Mr. Shane Madden reports

HYDREIGHT TECHNOLOGIES THROUGH ITS ASSOCIATED MEDICAL NETWORK NOW OFFER TIRZEPATIDE TO PRODUCT OFFERING WHICH ALSO FEATURES GLP-1 MEDICATIONS (LOW-COST SEMAGLUTIDE), NAD+ AND MORE

Hydreight Technologies Inc.'s over 3,000 nurses, 107 white-label locations and their patients now have access to tirzepatide through the Hydreight platform and its associated medical network in over 700 cities across 50 states in the United States.

Tirzepatide is an FDA-approved (U.S. Food and Drug Administration) medicine used to treat Type 2 diabetes mellitus and may be used off label for the treatment of obesity due to its effective weight loss qualities. It functions as a dual GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory polypeptide) agonist. Similar to other GLP-1 medicines, it is currently used as a second-line diabetic treatment and administered as a once-weekly subcutaneous injection.

Tirzepatide is in the same product line as semaglutide, which was launched and accessible through the Hydreight platform at the end of 2023. Tirzepatide and semaglutide injections are commonly used to treat Type 2 diabetes. It can also be used together with diet and exercise to help control blood sugar and has become popular to help with weight management. Tirzepatide and semaglutide are a GLP-1 receptor agonist and is only available with a doctor prescription and needs to be injected on a regular basis.

Since the beginning of the year, the company has seen significant growth and increased demand for its semaglutide offering. Between January and February, there was a 250-per-cent increase in the number of semaglutide orders. Semaglutide is injected on a monthly basis, and, due to the recurring nature, the company expects to see continued monthly growth.

Obesity, characterized by abnormal or excessive fat accumulation that poses risks to both physical health and mental health, has nearly tripled worldwide since 1975, according to the World Health Organization (WHO). Currently, it ranks as the fifth-leading risk factor for mortality globally. Factors such as dietary habits, physical activity levels and genetics contribute to the rising obesity rates, which are expected to continue increasing. According to Goldman Sachs, it is projected that, by 2030, the global market for anti-obesity medications (AOMs) could grow by more than 16 times to $100-billion. Based on current trends, over half of the global population will be overweight or obese by 2035, compared with 38 per cent in 2020, according to a World Obesity Atlas 2023 forecast.

"In our view, the chronic weight management market is at a turning point, with growth potential on the horizon. Weight loss and diabetes may just be the beginning for drugs like semaglutide and tirzepatide as reports increasingly suggest they may have far-reaching benefits for treating conditions as diverse as heart and liver disease, Parkinson's, anxiety, and addiction, sparking research among firms competing in pharma's latest gold rush," stated Shane Madden, chief executive officer of Hydreight.

The company's product offering aims to include various products and category options to ensure customers' needs are met. Every time a product is added, nurses must go through extensive training and onboarding to ensure the product is administered safely and correctly. All these products allow health care providers using the Hydreight platform to provide a higher level of medicine and provide a pathway to shift into medical essentials.

Mr. Madden commented: "One of our main strategic priorities for this year was to continue adding products to our offering, which provides more options for our nurses and customers. We will continue to add products throughout the year, which also provides better health care outcomes for our customers. Our focus is to start shifting from preventative wellness and our legacy IV [intravenous] therapy to essential care provided on an ongoing basis."

The company also announces an agreement with Fairfax Partners Inc. dated May 15, 2024, which will provide social media communication and marketing support for a one-month period for a fee of $20,000 plus GST (goods and services tax). The services include content development, social media campaign and analytics. The term of the Fairfax agreement is for a period of one month starting May 15, 2024, and includes an early termination provision. The company has options to renew the agreement after the one-month term at the same terms, and any renewal will be at the discretion of the company. Fairfax and its principals are arm's length to the company.

About Hydreight Technologies Inc.

Hydreight Technologies is building the largest mobile clinic network in the United States. Its proprietary, fully integrated platform hosts a network of nearly 3,000 nurses, over 100 doctors and a pharmacy network across 50 states. The platform includes a built-in, easy-to-use suite of fully integrated tools for accounting, documentation, sales, inventory, booking and managing patient data, which enable licensed health care professionals to provide services directly to patients at home, office or hotel. Hydreight empowers nurses, med spa technicians and other licensed health care professionals to deliver services independently, on their own terms, or to add mobile services to existing location-based operations. The Hydreight platform hosts a 503B pharmacy network servicing all 50 states and is closely affiliated with a U.S.-certified e-script and telemedicine provider network that provides services in over 650 cities and growing.

We seek Safe Harbor.